What is Perlara?
Perlara offers Guided Cures, a specialized service designed to assist individuals in navigating complex medical treatments and cures. The company leverages a team of leading researchers and clinicians, referred to as Cure Guides, who collaborate with families and a global research network to develop personalized treatment pathways. Perlara's approach is modality-agnostic, encompassing virtual consulting and model-agnostic drug repurposing services, all aimed at accelerating the discovery of novel therapeutic interventions. The company actively invites participation from families and scientists to contribute to its innovative model for advancing medical science.
How much funding has Perlara raised?
Perlara has raised a total of $9.4M across 2 funding rounds:
Angel/Seed
$2M
Unspecified
$7.4M
Angel/Seed (2014): $2M, investors not publicly disclosed
Unspecified (2017): $7.4M led by Novartis, Y Combinator, Radical Investments, Haystack Fund, Pivotal Capital Alpha, Homebrew Ventures, and Al-Hamra Group
Key Investors in Perlara
Novartis
Novartis is a global pharmaceutical giant headquartered in Switzerland, dedicated to developing and producing innovative medications and healthcare solutions across various therapeutic areas to improve patient outcomes worldwide.
Y Combinator
Y Combinator, founded in 2005 and based in Mountain View, California, is a prominent seed funding accelerator known for its early-stage investment in technology startups.
Homebrew Ventures
Homebrew is a venture capital firm based in San Francisco, California, specializing in early-stage investments and providing strategic guidance to technology startups.
What's next for Perlara?
With a substantial enterprise-level funding context and a recent strategic investment, Perlara is poised for significant expansion. The company's focus on personalized medicine and drug repurposing, supported by a network of researchers and clinicians, suggests a strategic direction towards scaling its Guided Cures platform. Future developments are likely to involve broadening its research collaborations and enhancing its virtual consulting capabilities to reach a wider patient and scientific community, thereby solidifying its position in the advanced therapeutics market.
See full Perlara company page
